- NCIt
- C132146
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (101)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00635791 | Phase I Study of Vorinostat and Sorafenib in Advanced Cancer | completed | Phase 1 | 36 | University of Colorado, DenverOTHER | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00907205 | A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors(SF112600106) | completed | Phase 1 | 44 | Semafore PharmaceuticalsINDUSTRY | 1 | Jun 13, 2013 |
| NCT00925743 | A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer | completed | Phase 1 | 76 | SanofiINDUSTRY | 1 | May 16, 2013 | clinicaltrials |
| NCT01380249 | PDM08 Clinical Trial in Advanced Solid Tumors | completed | Phase 1 | 22 | Prodimed S.A.OTHER | 1 | Jan 7, 2013 | clinicaltrials |
| NCT01416623 | A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies | terminated | Phase 1 | 44 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 21, 2012 | clinicaltrials |
| NCT00969410 | A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases | completed | Phase 1 | 19 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 12, 2012 | clinicaltrials |
| NCT00747734 | A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 35 | Genentech, Inc.INDUSTRY | 0 | Apr 20, 2011 | clinicaltrials |
| NCT01019941 | Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer(126ASC08Q) | completed | Phase 1 | 44 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 16, 2010 | clinicaltrials |
| NCT00516438 | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan | completed | Phase 1 | 48 | AstraZenecaINDUSTRY | 1 | Dec 8, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Jun 20, 2013source: clinicaltrials